Skip to content
Screener

Allogene Therapeutics ALLO Q1 2025 earnings

Reported May 13, 2025 · After market close

Revenue-
EPS-$0.28In line
EPS estimate-$0.28

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.5K
EPS estimate-$0.13

Financials

Q1 2025

Income statement

See full
Revenue--100%
Operating income-$65.2M+6.2%
Net income-$59.7M+8.1%
EPS (diluted)-$0.28+26.3%

Balance sheet

See full
Cash & equivalents$52.7M-14.0%
Total debt$88.9M-7.2%
Total equity$385.4M-16.5%
Total assets$508.0M-13.4%

Cash flow

See full
Operating cash flow-$52.9M+5.3%
CapEx$99.0K+1,138%
Free cash flow-$53.0M+5.1%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$317.21M-58.0%
Enterprise value$353.38M-55.3%

Returns & leverage

See full
Return on equity-59.6%+4.8pp
Debt / equity0.2×0.0×
Current ratio9.7×-3.1×

Segments

By segment

See full
Reportable Segment--100%

FAQ

When did Allogene Therapeutics report Q1 2025 earnings?
Allogene Therapeutics (ALLO) reported Q1 2025 earnings on May 13, 2025 after market close.
What were Allogene Therapeutics's Q1 2025 revenue and EPS?
Allogene Therapeutics reported revenue of - and eps of $-0.28 for Q1 2025.
Did Allogene Therapeutics beat estimates in Q1 2025?
EPS beat the consensus estimate of $-0.28 by $0.00.
How did Allogene Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $22.0K a year earlier and eps grew 26.3% from $-0.38.
Where can I find Allogene Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001737287-25-000063) and the 10-Q periodic report (0001737287-25-000064) directly on SEC EDGAR. The filing index links above go to sec.gov.